T Cells in Tumor Immunity

Romero, Pedro; Pittet, Mikaël J.; Zippelius, Alfred; Líénard, Danielle; Lejeune, Ferdy J.; Valmori, Danila; Speiser, Daniel E.; Cerottini, Jean‐Charles

doi:10.1002/3527600795.ch4

Cited by 2 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Presumably, the high frequency of the naïve repertoire for Melan‐A/MART‐1 accounts for the dominance of this response in HLA‐A2 melanoma patients. However, additional analysis of the antigen specificities among the CD8 tumor reactive CTL from metastatic melanoma lesions indicated the presence of additional specificities such as CTL against NY‐ESO‐1 (73), CAMEL (74), SSX‐2 (75) or MAGE‐10 (76) in the same lesion (77). More studies are required to fully appreciate the functional status of the lymphocytes freshly recovered from tumors.…”

Section: Discussionmentioning

confidence: 99%

Antigenicity and immunogenicity of Melan‐A/MART‐1 derived peptides as targets for tumor reactive CTL in human melanoma

Romero

Valmori

Pittet

et al. 2002

Immunological Reviews

Self Cite

143

119

View full text Add to dashboard Cite

Some cancer patients mount spontaneous T- and B-cell responses against their tumor cells. Autologous tumor reactive CD8 cytolytic T lymphocyte (CTL) and CD4 T-cell clones as well as antibodies from these patients have been used for the identification of genes encoding the target antigens. This knowledge opened the way for new approaches to the immunotherapy of cancer. In this review, we describe the characterization of the structure-function properties of the melanocyte/melanoma tumor antigen Melan-A/MART-1, the assessment of the T-cell repertoire available against this antigen in healthy individuals, and the analysis of naturally acquired and/or vaccine-induced CTL responses to this antigen in patients with metastatic melanoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Antigenicity and immunogenicity of Melan‐A/MART‐1 derived peptides as targets for tumor reactive CTL in human melanoma

Romero

Valmori

Pittet

et al. 2002

Immunological Reviews

Self Cite

143

119

View full text Add to dashboard Cite

show abstract

Expanding Roles for CD4 T Cells and Their Subpopulations in Tumor Immunity and Therapy

Dobrzanski¹

2013

Front. Oncol.

View full text Add to dashboard Cite

The importance of CD4 T cells in orchestrating the immune system and their role in inducing effective T cell-mediated therapies for the treatment of patients with select established malignancies are undisputable. Through a complex and balanced array of direct and indirect mechanisms of cellular activation and regulation, this functionally diverse family of lymphocytes can potentially promote tumor eradication, long-term tumor immunity, and aid in establishing and/or rebalancing immune cell homeostasis through interaction with other immune cell populations within the highly dynamic tumor environment. However, recent studies have uncovered additional functions and roles for CD4 T cells, some of which are independent of other lymphocytes, that can not only influence and contribute to tumor immunity but paradoxically promote tumor growth and progression. Here, we review the recent advances in our understanding of the various CD4 T cell lineages and their signature cytokines in disease progression and/or regression. We discuss their direct and indirect mechanistic interplay among themselves and with other responding cells of the antitumor response, their potential roles and abilities for “plasticity” and memory cell generation within the hostile tumor environment, and their potentials in cancer treatment and immunotherapy.

show abstract

T Cells in Tumor Immunity

Cited by 2 publications

References 52 publications

Antigenicity and immunogenicity of Melan‐A/MART‐1 derived peptides as targets for tumor reactive CTL in human melanoma

Antigenicity and immunogenicity of Melan‐A/MART‐1 derived peptides as targets for tumor reactive CTL in human melanoma

Expanding Roles for CD4 T Cells and Their Subpopulations in Tumor Immunity and Therapy

Contact Info

Product

Resources

About